# Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Study · id `cardio:ct-nct03071692` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03071692](<https://clinicaltrials.gov/study/NCT03071692>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03071692

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 10544 participants.

## Technical summary

Registry record NCT03071692. Randomized; quadruple masking; primary purpose prevention. Start 2017-03-23 (actual); primary completion 2022-07-27 (actual). Results posted on 2025-09-25.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 10544 participants (enrolled count; ClinicalTrials.gov record NCT03071692, source copy `cardio:ctgov-nct03071692-2025-09-25`, retrieved 2026-10-31)
- Started: 2017-03-23 (actual) (ClinicalTrials.gov record NCT03071692, source copy `cardio:ctgov-nct03071692-2025-09-25`, retrieved 2026-10-31)
- Primary completion: 2022-07-27 (actual) (ClinicalTrials.gov record NCT03071692, source copy `cardio:ctgov-nct03071692-2025-09-25`, retrieved 2026-10-31)
- Completion: 2022-07-27 (actual) (ClinicalTrials.gov record NCT03071692, source copy `cardio:ctgov-nct03071692-2025-09-25`, retrieved 2026-10-31)
- Results first posted: 2025-09-25 (ClinicalTrials.gov record NCT03071692, source copy `cardio:ctgov-nct03071692-2025-09-25`, retrieved 2026-10-31)
- Countries: United States; Argentina; Brazil; Bulgaria; Canada; Colombia; Czechia; Denmark; France; Germany; Hungary; India; Israel; Japan; Mexico; Netherlands; Poland; Puerto Rico; Romania; Russia; Slovakia; South Africa; Spain; Ukraine; United Kingdom (ClinicalTrials.gov record NCT03071692, source copy `cardio:ctgov-nct03071692-2025-09-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03071692-2025-09-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
- Acronym: PROMINENT
- Condition: Type2 Diabetes
- Condition: Dyslipidemia
- Intervention (Drug): K-877
- Intervention (Drug): Placebo
- Lead sponsor: Kowa Research Institute, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Brigham and Women's Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Kowa Research Institute, Inc. (`cardio:org-kowa-research-institute-inc`)
- Registry lists this organization as a collaborator: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (`cardio:pubmed-36342113`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 237abfeab941a1a7e993c75b8d99d30b20c1abf4b2adc985c5de144812f51edc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
